1463-52-1

Basic information

• Product Name: ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE
• Synonyms: ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE;Acetic acid, 2-cyano-2-[1-(phenylMethyl)-4-piperidinylidene]-, ethyl ester;(1-Benzyl-piperidin-4-ylidene)-cyano-acetic acid ethyl ester
• CAS NO: 1463-52-1
• Molecular Formula: C₁₇H₂₀N₂O₂
• Molecular Weight: 284.35
• Mol File: 1463-52-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 64-67°C
• Boiling Point: 430.4°Cat760mmHg
• Flash Point: 214.1°C
• Appearance: /
• Density: 1.148g/cm³
• Vapor Pressure: 1.31E-07mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• PKA: 6.74±0.20(Predicted)
• CAS DataBase Reference: ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE(1463-52-1)
• EPA Substance Registry System: ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE(1463-52-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1463-52-1(Hazardous Substances Data)

Usage

General Description

ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE is a chemical compound with a molecular formula C21H22N2O2. It is an organic compound composed of carbon, hydrogen, nitrogen, and oxygen atoms. ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE is a piperidinylidene derivative with a benzyl and cyanoacetylated group. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals.ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE is a crystalline solid that is slightly soluble in water and soluble in organic solvents. It is important to handle this compound with care and follow proper safety protocols, as it may pose health and environmental risks if not used and disposed of properly. Overall, ETHYL 2-(1-BENZYL-4-PIPERIDINYLIDENE)-2-CYANOACETATE is a versatile chemical compound with various applications in the field of organic chemistry and drug development.

InChI:InChI=1/C17H20N2O2/c1-2-21-17(20)16(12-18)15-8-10-19(11-9-15)13-14-6-4-3-5-7-14/h3-7H,2,8-11,13H2,1H3

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 105-56-6 ethyl 2-cyanoacetate 
• 64-17-5 ethanol 
• 616897-44-0 2-(1-benzylpiperidin-4-ylidene)malononitrile 

Downstream Products

• 1082204-31-6 C₃₃H₄₁N₃O₅ 
• 1082204-32-7 C₃₃H₄₁N₃O₅ 
• 1082204-05-4 C₂₅H₃₆N₂O₄ 
• 1082204-06-5 C₂₄H₃₄N₂O₅ 
• 78056-67-4 1-(phenylmethyl)-4-piperidineacetonitrile 
• 86945-27-9 1-benzyl-4-cyanomethylpiperidine-4-carbonitrile 
• 1187036-97-0 benzyl 2,3,4-tri-O-benzyl-6-O-(N-(2-ethyl-2,8-diazaspiro[4,5]decane-1,3-dione)aminocarbonyl)-β-D-glucopyranoside 
• 1463-48-5 8-benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 1463-47-4 8-benzyl-2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 2079-24-5 2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 

Relevant articles and documents

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors

Abstract Some novel coumarin-3-carboxamide derivatives linked to N-benzylpiperidine scaffold were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors. The screening results showed that most of compounds exhibited potent anti-AChE activity in the range of nM concentrations. Among them, compound 10c bearing an N-ethylcarboxamide linker and a 6-nitro substituent showed the most potent activity (IC50 = 0.3 nM) and the highest selectivity (SI = 26,300). Compound 10c was 46-fold more potent than standard drug donepezil against AChE. The kinetic study revealed that compound 10c exhibited mixed-type inhibition against AChE. Protein-ligand docking study demonstrated that the target compounds have dual binding site interaction mode and these results are in agreement with kinetic study.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.